American Heart Technologies, LLC, et al. v. Amirhossein Jaberzadeh Ansari, et al.

District Court, C.D. California·Decided April 15, 2026·No. 2:22-cv-08387·Unknown

Opinion

O Case No.: 2:22-cv-08387-MEMF-RAO

et al., ORDER GRANTING MOTION TO STAY Plaintiff(s), ENFORCEMENT OF JUDGMENT PENDING APPEAL AND TO APPROVE v. SUPERSEDEAS BOND [DKT. NO. 126]

AMIRHOSSEIN JABERZADEH ANSARI, et al., Defendant(s).

Before the Court is a Motion to Stay Enforcement of Judgment Pending Appeal and to Approve Supersedeas Bond filed by Plaintiffs American Heart Technologies, LLC (“American Heart”) and HeartLung Corporation (“HeartLung”). Dkt. No. 126 (“Motion”). The Court finds this matter appropriate for resolution without oral argument. See Fed. R. Civ. P. 78(b); C.D. Cal. L.R. 7- 15. For the reasons stated herein, the Court hereby GRANTS the Motion.

SUMMARY OF ORDER FOR PRO SEA LNISTAIRGIA NT AMIRHOSSEIN JABERZADEH The Court addresses Plaintiffs’ Motion to Stay Enforcement of Judgment Pending Appeal and to Approve Supersedeas Bond. Motion. Plaintiffs request the Court: (1) stay enforcement of the judgment awarding your Motion for Attorney’s Fees and Costs, Dkt. No. 102, pending appeal; and (2) approve the supersedeas bond in the amount of $65,024. This Order will explain why the Court GRANTS Plaintiffs’ Motion. BACKGROUND I. Factual Background Plaintiff and Counterclaim Defendant American Heart Technologies, LLC (“American Heart”) is a medical research and development company that invests in and develops medical technologies that focus on early detection of cardiovascular diseases, lung cancer, and other medical conditions. Plaintiff and Counterclaim Defendant HeartLung Corporation (“HeartLung”) is a startup venture of American Heart.1 American Heart and HeartLung collaborate with university medical centers to develop and commercialize advanced artificial intelligence (“AI”) technologies for early detection of medical conditions. Counterclaim Defendant Morteza Naghavi (“Naghavi”) is the founder and Chief Executive Officer of HeartLung.2 Defendant and Counterclaimant Amirhossein Jaberzadeh Ansari is a former contractor of HeartLung. This case concerns American Heart and HeartLung’s allegations that Ansari misappropriated Plaintiffs’ trade secrets, breached relevant contracts and duties, and converted Plaintiffs’ trade secrets for his own personal use. II. Procedural History On November 16, 2022, Plaintiffs filed a complaint against Ansari and Does 1 through 10. Dkt. No. 1. Plaintiffs filed a First Amended Complaint on December 16, 2022, alleging four causes of action: (1) trade secret misappropriation under federal law (18 U.S.C. § 1836, et seq.); (2) breach 1 The Court will refer to American Heart and HeartLung, collectively, as the “Plaintiffs.” of contract; (3) trade secret misappropriation under state law (Cal. Civ. Code § 3426); and (4) conversion. See generally Dkt. No. 11 (“First Amended Complaint” or “FAC”). On April 3, 2023, Ansari filed an Answer and Counterclaim. Dkt. No. 18. Ansari asserted fifteen affirmative defenses and twelve counterclaims against American Heart, HeartLung, Naghavi, and Roes 1 through 10. See id. At the summary judgment stage, Ansari sought summary judgment as to Plaintiffs’ four causes of action and his twelve state-law counterclaims. Dkt. Nos. 63, 63-7. On April 21, 2025, this Court granted summary judgment in part and dismissed Plaintiffs’ two trade secret claims, breach of contract claim, and conversion claim. Dkt. No. 76 (“SJ Order”). The Court declined to rule on whether Ansari is entitled to summary judgment on his state law counterclaims and ordered Plaintiffs to show cause as to why the Court should exercise supplemental jurisdiction over the remaining counterclaims. Id. On May 5, 2025, Plaintiffs filed a response in favor of the Court declining to exercise supplemental jurisdiction. Dkt. No. 80. On June 4, 2025, the Court dismissed Ansari’s twelve state- law counterclaims without prejudice so that Ansari may refile them in California state superior court. Dkt. No. 92. On May 8, 2025, Ansari filed an Amended Motion for Attorney’s Fees and Costs. Dkt. No. 82. Plaintiffs filed an opposition and Ansari filed a reply. Dkt. Nos. 84, 86. On August 19, 2025, the Court GRANTED IN PART Ansari’s Motion for Attorney’s Fees and Costs, awarding attorney’s fees to Ansari in the amount of $41,728.73 and costs in the amount of $1,620 for a total of $43,348.73. Dkt. No. 102. On October 17, 2025, Plaintiffs filed a Notice of Appeal. Dkt. No. 108. The Ninth Circuit provided a briefing schedule on October 20, 2025. Dkt. No. 110. On February 21, 2026, Plaintiffs filed the instant Motion. Motion. On March 25, 2026, Ansari filed an Opposition to the Motion. Dkt. No. 130 (“Opposition”). On April 2, 2026, Plaintiffs filed a Reply. Dkt. No. 131 (“Reply”). III. Applicable Law Federal Rule of Civil Procedure 62(b) provides: Aort oatnhye rt ismeceu arfitteyr. jTuhdeg mstaeyn tt aisk eesn teefrfeedc,t aw phaernty t hme acyo uorbtt aaipnp aro svtaeys tbhye pbroonvdid oirn go tah ebro nd security and remains in effect for the time specified in the bond or other security. Fed. R. Civ. P. 62(b). Federal Rule of Civil Procedure 62(d) provides: While an appeal is pending from an interlocutory order or final judgment that grants, continues, modifies, refuses, dissolves, or refuses to dissolve or modify an injunction, the court may suspend, modify, restore, or grant an injunction on terms for bond or other terms that secure the opposing party’s rights. Fed. R. Civ. P. 62(d). “With respect to a case arising in the federal system it seems to be accepted that a party taking an appeal from the District Court is entitled to a stay of a money judgment as a matter of right if he posts a bond in accordance with Rule 62(d).” Am. Mfrs. Mut. Ins. Co. v. Am. Broadcasting-Paramount Theatres, Inc., 87 S. Ct. 1, 3 (1966). “Rule 62(d) is a purely procedural mechanism to preserve the status quo during a stay pending appeal of a district court decision . . . .” Bass v. First Pac. Networks, Inc., 219 F.3d 1052, 1055 (9th Cir. 2000). IV. Discussion Plaintiffs move to: (1) stay enforcement of the judgment awarding the Motion for Attorney’s Fees and Costs, Dkt. No. 102, pending appeal; and (2) approve the supersedeas bond in the amount of $65,024. See generally Motion. For the reasons discussed below, the Court finds that a stay is warranted, Plaintiffs’ supersedeas bond is reasonable, and GRANTS the Motion. A. A Stay Is Warranted Under Federal Rule of Civil Procedure 62(b). Plaintiffs cite to Rule 62(b), arguing that the enforcement of the judgment entered on August 19, 2025, awarding Ansari attorney’s fees and costs of $43,348.73, Dkt. No. 102, should be stayed given that Plaintiffs have timely appealed, Dkt. No. 108. Motion at 3. Plaintiffs assert that a stay is “is appropriate to prevent irreparable harm and unnecessary enforcement activity while appellate review proceeds.” Id. In response, Ansari claims that: (1) Plaintiffs’ delay in seeking bond relief weighs against a stay; (2) there is a risk of nonpayment by the shell entities; (3) Plaintiffs have failed to comply with discovery; (4) the requested stay is an attempt to pre

Free access — add to your briefcase to read the full text and ask questions with AI

American Heart Technologies, LLC, et al. v. Amirhossein Jaberzadeh Ansari, et al., (C.D. Cal. 2026).

American Heart Technologies, LLC, et al. v. Amirhossein Jaberzadeh Ansari, et al. (American Heart Technologies, LLC, et al. v. Amirhossein Jaberzadeh Ansari, et al.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related